ICD-O-3 Implementation Guidelines
ICD-O-3.2 Implementation Documents for Implementation in 2026
- 2026 ICD-O-3.2 Coding Guidelines – 4/18/2025
- 2026 ICD-O-3.2 Table 1 Numeric – 4/18/2025
- 2026 ICD-O-3.2 Table 2 Alpha Table – 4/23/2025
WHO IARC ICD-O-3.2
- WHO IARC ICD-O-3.2 Excel Table – 1/1/2021 – The date North American registries adopted 3.2 for use.
Annotated Histology List
- Annotated Histology List Description and Disclaimer 5/1/2025
- Annotated Histology List – 5/1/2025
These documents address the implementation of ICD-O-3 for cases diagnosed on or after January 1, 2024.
ICD O 3.2 Implementation Documents for Implementation in 2024
- 2024 ICD-O-3.2 Coding Guidelines – 8/2/2023
- 2024 ICD-O-3.2 Table 1 Numeric – 8/2/2023
- 2024 ICD-O-3.2 Table 2 Alpha Table – 1/30/2024 (Behavior corrected for TFE3-rearranged RCC (C64.9) and TFE3-rearranged RCC. Corrected from 8311/1 to 8311/3).
These documents address the Implementation of ICD-O-3 for cases diagnosed on or after January 1, 2023.
ICD-O-3.2 Implementation Documents for implementation in 2023
- 2023 ICD-O-3.2 Coding Guidelines – 9/28/2022
- 2023 ICD-O-3.2 Table 1 Numeric – 9/28/2022
- 2023 ICD-O-3.2 Table 2 Alpha Table – 9/28/2022
- Addendum to 2022 ICD-O-3.2 – 9/13/2022
WHO IARC ICD-O-3.2
- WHO IARC ICD-O-3.2 Excel Table – 1/1/2021 The date North American registries adopted 3.2 for use.
Annotated Histology List
- Annotated Histology List Description and Disclaimer – 7/29/2021
- Annotated Histology List 1/31/23 (Corrected misspelling for terms associated with 9505/0 and 9738/1)
_______________
These documents address the Implementation of ICD-O-3 for cases diagnosed on or after January 1, 2022.
ICD-O-3.2 Implementation Documents for implementation in 2022
- 2022 ICD-O-3.2 Coding Guidelines – 7/29/2021
- 2022 ICD-O-3.2 Table 1 Numeric – 12/14/2021
- 2022 ICD-O-3.2 Table 2 Alpha Table – 9/22/2021
- ICD-O-3.2 Coding Table Excel – 7/29/2021
Annotated Histology List
- Annotated Histology List – 7/29/2021
_______________
These documents address the Implementation of ICD-O-3 for cases diagnosed on or after January 1, 2021.
ICD O 3.2 Implementation Documents
- 2021 ICD-O-3.2 Coding Guidelines – 10/05/2020
- 2021 ICD-O-3.2 Tables 1-5 (tables with new term, new codes, changed behaviors, etc) – 10/01/2020
- 2021 ICD-O-3.2 Table 6 Numeric (combined tables 1-5 in numeric order) – 11/10/2020
- 11/10/20 Paraganglioma, NOS histology code corrected (8680 is correct code)
- 2021 ICD-O-3.2 Table 7 Alpha Table (combined tables 1-5 in alpha order)- 11/10/2020
- 11/10/20 Paraganglioma, NOS histology code corrected (8680 is correct code)
- 2021 ICD-O-3.2 Coding Table Excel (full list of ICD 3.2 histology codes)- 10/01/2020
Annotated Histology List
- Annotated Histology List
- Updated 11/10/20-Superficial Spreading Adenocarcinoma (8143/3) was changed to TRUE.
_______________
2018 ICD-O-3 Implementation Guidelines (December 2017)
These documents address the implementation of ICD-O-3 for cases diagnosed on or after January 1, 2018.
- 2018 ICD-O-3 Coding Guidelines – 1/10/2018
- 2018 ICD-O-3 Coding Table .pdf – 8/22/2018 (sorted by numeric order)
- 2018 ICD-O-3 Coding Table .pdf – 8/22/2018 (sorted by alpha order)
- Errata – 8/22/2018
*The tables were originally posted on 12/20/2017.
____________
2014 ICD-O-3 Implementation Guidelines (December 2013)
This document addresses the implementation of ICD-O-3 for cases diagnosed on or after January 1, 2014.
- Guidelines for ICD-O-3 Update Implementation – Revised April 2014
______________________
-
ICD-O-3 Implementation Guidelines (November 2000)
This document addresses the implementation of ICD-O-3 for cases diagnosed on or after January 1, 2001
